Clinical Trials Logo

Clinical Trial Summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.


Clinical Trial Description

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01470638
Study type Observational
Source Göteborg University
Contact
Status Completed
Phase
Start date June 2009
Completion date April 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05985915 - A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. Phase 3